Skip to content
Screener

AnaptysBio, Inc. ANAB Biopharma Company — Other Nonoperating Income Expense

Other segment segments

Royalty Management Company
$0

Similar metrics at other companies

VAN
VANIBiopharm Division — Other Nonoperating Income Expense
-$209K+29.4%
Consolidated Water Company logo
CWCOBulk — Other Nonoperating Income Expense
$10.02K-32.9%
Consolidated Water Company logo
CWCOCorporate — Other Nonoperating Income Expense
$115
Consolidated Water Company logo
CWCOServices — Other Nonoperating Income Expense
$1-97.2%
BioSig Technologies, Inc. logo
STEXCorporate — Other Nonoperating Income Expense
$73K+587%
KRAKacquisition logo
KRAQSingle — Other Nonoperating Income Expense
$0

Other financials

Income statement

See full
Revenue$25.6M-8.0%
Operating income-$34.6M-25.8%
Net income-$52.9M-34.5%
EPS (diluted)-$1.84-43.8%

Balance sheet

See full
Cash & equivalents$248.5M+152%
Total debt$13.6K-99.9%
Total equity$12.7M-62.5%
Total assets$329.7M-21.9%

Cash flow

See full
Operating cash flow-$25.9M-142%
CapEx$17.0K-51.4%
Free cash flow-$25.9M-142%

Valuation

See full
Market cap$1.62B+145%
Enterprise value$1.37B+117%
P/S+1.6×

Profitability

See full
Operating margin17.6%+9.6pp
Net margin-49.9%-22.6pp
FCF margin1.9%+1.0pp

Returns & leverage

See full
Return on equity-343.8%-1,012pp
Debt / equity-0.5×
Current ratio7.6×-0.7×

Where this comes from

Reported directly by AnaptysBio, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.

The source filing: AnaptysBio, Inc.’s 10-Q, filed May 12, 2026.

Filed
May 12, 2026, 4:20 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-219515
Line itemBiopharmaRoyalty ManagementTotal
(Loss) income from operations(52,811)18,174(34,637)
Interest income2,3283252,653
Non-cash interest expense(20,859)(20,859)
Other expense, net(1)(1)
Total other income (expense), net2,327(20,534)(18,207)
Loss before income taxes(50,484)(2,360)(52,844)
Provision for income taxes(40)(40)
Segment net loss(50,484)(2,400)(52,884)

Item 1. Consolidated Financial Statements

FAQ

What is AnaptysBio, Inc.'s biopharma company — other nonoperating income expense?
AnaptysBio, Inc. (ANAB) reported biopharma company — other nonoperating income expense of -$1K in Q1 2026.
How has AnaptysBio, Inc.'s biopharma company — other nonoperating income expense changed year-over-year?
AnaptysBio, Inc.'s biopharma company — other nonoperating income expense increased by 85.7% year-over-year, from -$7K to -$1K.
What does biopharma company — other nonoperating income expense mean?
This metric captures miscellaneous income or expenses that are not directly related to the company's core biopharmaceutical operations. It includes items such as gains or losses on asset disposals, foreign exchange fluctuations, or other non-recurring financial events. It provides a view of peripheral financial impacts on the company's bottom line.

Ask your AI about AnaptysBio, Inc.'s biopharma company — other nonoperating income expense.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude